Aurobindo gets US nod to market analgesic

The Hyderabad-based firm has received USFDA approval to market its pain-relieving drug, Meloxicam, in the US market.

Hyderabad-based Aurobindo Pharma Ltd on Thursday said it has received US Food and Drug Administration's approval to market its pain relieving drug, Meloxicam, in the US market.

HT Image

Meloxicam is a generic version of Boehringer Ingelheim's pain relieving drug, 'Mobic', the company informed the Bombay Stock Exchange.

The company has received the approval to market Meloxicam in 7.5 mg and 15 mg dosages in tablet form, the statement said.

Meloxicam is a non-steroidal anti-inflammatory analgesic, which is used to reduce pain, tenderness, swelling, fever and stiffness of joints associated with arthritis, the statement said.